152 related articles for article (PubMed ID: 36729404)
21. Pharmacokinetics, Safety, and Efficacy of Gadopiclenol in Pediatric Patients Aged 2 to 17 Years.
Jurkiewicz E; Tsvetkova S; Grinberg A; Pasquiers B
Invest Radiol; 2022 Aug; 57(8):510-516. PubMed ID: 35318970
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength.
Fries P; Massmann A; Robert P; Corot C; Laschke MW; Schneider G; Buecker A; Müller A
Invest Radiol; 2019 Sep; 54(9):549-558. PubMed ID: 31033675
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Safety Assessment of Gadopiclenol: A High-Relaxivity Macrocyclic Gadolinium-Based MRI Contrast Agent.
Gendron C; Bourrinet P; Dencausse A; Fretellier N
Invest Radiol; 2024 Feb; 59(2):108-123. PubMed ID: 37921752
[TBL] [Abstract][Full Text] [Related]
24. Gadolinium Presence in the Brain After Administration of the Liver-Specific Gadolinium-Based Contrast Agent Gadoxetate: A Systematic Comparison to Multipurpose Agents in Rats.
Jost G; Frenzel T; Boyken J; Schoeckel L; Pietsch H
Invest Radiol; 2019 Aug; 54(8):468-474. PubMed ID: 30932931
[TBL] [Abstract][Full Text] [Related]
25. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases.
Fan B; Li M; Wang X; Xu Y; Li F; Zhang L; Jiang J; Jiang Y
J Magn Reson Imaging; 2017 Jun; 45(6):1827-1834. PubMed ID: 27696616
[TBL] [Abstract][Full Text] [Related]
27. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).
Seidl Z; Vymazal J; Mechl M; Goyal M; Herman M; Colosimo C; Pasowicz M; Yeung R; Paraniak-Gieszczyk B; Yemen B; Anzalone N; Citterio A; Schneider G; Bastianello S; Ruscalleda J
AJNR Am J Neuroradiol; 2012 Jun; 33(6):1050-8. PubMed ID: 22383237
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the Contrast Enhancement Performance of Gadopiclenol for Magnetic Resonance Angiography in Healthy Rabbits and Pigs.
Hugon G; Adriaensen H; Wintrebert M; Arnould L; Serfaty JM; Robert P
Invest Radiol; 2024 May; ():. PubMed ID: 38709660
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
[TBL] [Abstract][Full Text] [Related]
30. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity.
Robic C; Port M; Rousseaux O; Louguet S; Fretellier N; Catoen S; Factor C; Le Greneur S; Medina C; Bourrinet P; Raynal I; Idée JM; Corot C
Invest Radiol; 2019 Aug; 54(8):475-484. PubMed ID: 30973459
[TBL] [Abstract][Full Text] [Related]
31. Effect of at Least 10 Serial Gadobutrol Administrations on Brain Signal Intensity Ratios on T1-Weighted MRI in Children: A Matched Case-Control Study.
Ozturk K; Nascene D
AJR Am J Roentgenol; 2021 Sep; 217(3):753-760. PubMed ID: 33112200
[No Abstract] [Full Text] [Related]
32. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine.
Chang JM; Moon WK; Cha JH; Jung EJ; Cho N; Kim SJ
Invest Radiol; 2010 Oct; 45(10):655-61. PubMed ID: 20808238
[TBL] [Abstract][Full Text] [Related]
33. Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read.
Koenig M; Schulte-Altedorneburg G; Piontek M; Hentsch A; Spangenberg P; Schwenke C; Harders A; Heuser L
Eur Radiol; 2013 Dec; 23(12):3287-95. PubMed ID: 23824152
[TBL] [Abstract][Full Text] [Related]
34. Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.
Funck-Brentano C; Felices M; Le Fur N; Dubourdieu C; Desché P; Vanhoutte F; Voiriot P
Br J Clin Pharmacol; 2020 Nov; 86(11):2174-2181. PubMed ID: 32302009
[TBL] [Abstract][Full Text] [Related]
35. Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine.
Durmus T; Schilling R; Doeblin P; Huppertz A; Hamm B; Taupitz M; Wagner M
Invest Radiol; 2012 Mar; 47(3):183-8. PubMed ID: 22183078
[TBL] [Abstract][Full Text] [Related]
36. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
[TBL] [Abstract][Full Text] [Related]
37. P03277-A New Approach to Achieve High-Contrast Enhancement: Initial Results of an Experimental Extracellular Gadolinium-Based Magnetic Resonance Contrast Agent.
Fries P; Müller A; Seidel R; Robert P; Denda G; Menger MD; Schneider G; Buecker A
Invest Radiol; 2015 Dec; 50(12):835-42. PubMed ID: 26186281
[TBL] [Abstract][Full Text] [Related]
38. MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T.
Saake M; Langner S; Schwenke C; Weibart M; Jansen O; Hosten N; Doerfler A
Eur Radiol; 2016 Mar; 26(3):820-8. PubMed ID: 26123410
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of gadobutrol-enhanced MRA of the renal arteries: Results from GRAMS (Gadobutrol-enhanced renal artery MRA study), a prospective, intraindividual multicenter phase 3 blinded study.
Fabrega-Foster KE; Agarwal S; Rastegar N; Haverstock D; Agris JM; Kamel IR
J Magn Reson Imaging; 2018 Feb; 47(2):572-581. PubMed ID: 28574637
[TBL] [Abstract][Full Text] [Related]
40. Intraindividual Analysis of Signal Intensity Changes in the Dentate Nucleus After Consecutive Serial Applications of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Radbruch A; Weberling LD; Kieslich PJ; Hepp J; Kickingereder P; Wick W; Schlemmer HP; Bendszus M
Invest Radiol; 2016 Nov; 51(11):683-690. PubMed ID: 27495187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
